Table 1 Clinical Features and TSLC1 Expression Profiles of 47 Patients with Pulmonary Adenocarcinoma

From: Expression of the TSLC1 Adhesion Molecule in Pulmonary Epithelium and Its Down-Regulation in Pulmonary Adenocarcinoma Other than Bronchioloalveolar Carcinoma

Case no.

Age/sex

TNMa

Pathologic stageb

Histologic subtype

Differentiation grade

TSLC1 expressionc

  

pT

pN

M

   

Level

Componentd

1

56/F

1

0

0

I

BAC

 

N

Lepidic

2

58/F

1

0

0

I

BAC

 

N

Lepidic

3

74/F

1

0

0

I

BAC

 

N

Lepidic

4

61/M

1

0

0

I

BAC

 

N

Lepidic

5

56/F

1

0

0

I

BAC

 

N

Lepidic

6

69/F

1

0

0

I

BAC

 

N

Lepidic

7

74/F

1

0

0

I

BAC

 

N

Lepidic

8

62/F

1

0

0

I

BAC

 

N

Lepidic

9

40/F

1

0

0

I

BAC

 

N

Lepidic

10

62/F

2

1

0

II

BAC

 

N

Lepidic

11

71/M

2

0

0

II

BAC

 

N

Lepidic

12

71/M

1

1

0

II

BAC

 

N

Lepidic

13

59/F

1

1

0

II

BAC

 

N

Lepidic

14

63/M

2

1

0

II

BAC

 

N

Lepidic

15

55/M

2

2

0

IIIA

BAC

 

N

Lepidic

16

78/M

4

1

0

IIIB

BAC

 

N

Lepidic

17

52/M

1

1

0

II

Papillary

Well

N

Lepidic

18

72/F

2

1

0

II

Papillary

Well

N

Lepidic

19

67/M

2

2

0

IIIA

Papillary

Well

D

 

20

74/M

2

2

0

IIIA

Papillary

Well

D

 

21

73/F

2

2

0

IIIA

Papillary

Well

N

Lepidic

22

82/M

2

2

0

IIIA

Papillary

Well

D

 

23

37/M

1

2

0

IIIA

Papillary

Well

D

 

24

67/M

1

2

0

IIIA

Papillary

Moderate

D

 

25

54/M

4

2

0

IIIB

Papillary

Well

D

 

26

79/M

4

Xe

0

IIIB

Papillary

Well

N

Lepidic

27

74/M

4

2

0

IIIB

Papillary

Well

D

 

28

53/F

4

2

0

IIIB

Papillary

Moderate

D

 

29

62/F

2

2

1

IV

Papillary

Well

N

Lepidic

30

75/M

2

2

1

IV

Papillary

Moderate

D

 

31

69/M

3

0

1

IV

Papillary

Poor

D

 

32

53/F

1

0

0

I

Solid

Poor

D

 

33

73/M

1

0

0

I

Solid

Poor

D

 

34

60/M

3

0

0

II

Solid

Poor

N

Solid

35

55/M

2

1

0

II

Solid

Poor

D

 

36

62/M

2

0

0

I

Mixed

Moderate

N

Lepidic

37

68/M

2

0

0

I

Mixed

Poor

D

 

38

70/M

1

0

0

I

Mixed

Poor

N

Acinar

39

63/M

2

0

0

I

Mixed

Poor

D

 

40

45/F

4

1

0

II

Mixed

Well

N

Lepidic

41

52/M

2

1

0

II

Mixed

Poor

D

 

42

73/F

1

1

0

II

Mixed

Poor

D

 

43

72/F

1

1

0

II

Mixed

Poor

N

Solid

44

77/M

3

0

0

II

Mixed

Poor

N

Lepidic

45

68/F

1

2

0

II

Mixed

Moderate

D

 

46

71/M

2

2

0

IIIA

Mixed

Poor

N

Acinar

47

72/F

4

1

0

IIIB

Mixed

Poor

D

 
  1. BAC, bronchioloalveolar carcinoma; D, decreased; F, female; M, male; N, nondecreased; TNM, tumor, node, metastasis; TSLC1, tumor suppressor in lung cancer-1.
  2. aThe anatomic extent of the tumors were assessed by the TNM system: increasing size of primary tumor as T1, T2, T3, or T4; advancing nodal disease as N0, N1, or N2; and the absence or presence of metastases as M0 or M1, respectively.
  3. bStage grouping of the TNM subsets was according to the International System for Staging Lung Cancer: stage I, T1N0M0 and T2N0M0; stage II, T1N1M0, T2N1M0, and T3N0M0; stage IIIA, T3N1M0, T1N2M0, T2N2M0, and T3N2M0; stage IIIB, T4 any N M0, and any T N3M0; and stage IV, any T any N M1.
  4. cA summary of the results obtained by Western blot and immunohistochemical analyses in the present study.
  5. dTumors judged nondecreased were subjected to immunohistochemistry, and the major histologic components that contained TSLC1 signals are shown.
  6. eRegional lymph nodes cannot be assessed.
Back to article page